Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine
Identifieur interne : 005D25 ( Main/Exploration ); précédent : 005D24; suivant : 005D26Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine
Auteurs : S. B. Blunt [Royaume-Uni] ; Jenner ; C. D. Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1993.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Animal, Animals, Antiparkinson agent, Carbidopa (pharmacology), Cell Count (drug effects), Cell Survival (drug effects), Dominance, Cerebral (drug effects), Dominance, Cerebral (physiology), Dopa, Dopamine (physiology), Experimental disease, Female, L‐dopa, Neural Pathways (cytology), Neural Pathways (drug effects), Neurons (cytology), Neurons (drug effects), Neurotoxicity, Oxidopamine (toxicity), Parkinson disease, Parkinson's disease, Rat, Rats, Rats, Wistar, Receptors, Dopamine (drug effects), Substantia Nigra (cytology), Substantia Nigra (drug effects), Tegmentum Mesencephali (cytology), Tegmentum Mesencephali (drug effects), Toxicity, Tyrosine 3-Monooxygenase (metabolism), Ventral tegmental area (VTA).
- MESH :
- chemical , drug effects : Receptors, Dopamine.
- chemical , metabolism : Tyrosine 3-Monooxygenase.
- chemical , pharmacology : Carbidopa.
- cytology : Neural Pathways, Neurons, Substantia Nigra, Tegmentum Mesencephali.
- drug effects : Cell Count, Cell Survival, Dominance, Cerebral, Neural Pathways, Neurons, Substantia Nigra, Tegmentum Mesencephali.
- physiology : Dominance, Cerebral, Dopamine.
- chemical , toxicity : Oxidopamine.
- Animals, Female, Rats, Rats, Wistar.
Abstract
Ever since the introduction of levo‐3, 4‐dihydroxyphenylalanine (L‐dopa) for the treatment of Parkinson's disease, there has been concern that it might accelerate the degeneration of dopamine neurones. Using rats with a unilateral 6‐hydroxydopamine (6‐OHDA) lesion of the medial forebrain bundle (MFB), we have studied the effect of chronic L‐dopa treatment on the survival of dopamine cells which remain in the ventral tegmental area (VTA) ipsilateral to a 6‐OHDA lesion. Following lesion surgery, rats were treated with L‐dopa and carbidopa administered in the drinking water for 27 weeks. At the end of the treatment period, the number of dopamine cells remaining in each of the lesioned and intact substantia nigra (SN) and VTA were assessed, using tyrosine hydroxylase immunohistochemistry. Chronic L‐dopa treatment resulted in an apparent reduction in the number of dopamine neurones remaining in the VTA ipsilateral to the lesion, whereas it had no effect on the number of dopamine cells remaining in the intact SN and VTA. This finding suggests a possible suppressive effect in vivo of L‐dopa on dopamine cells in the midbrain of adult animals that have been previously exposed to 6‐OHDA.
Url:
DOI: 10.1002/mds.870080202
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002036
- to stream Istex, to step Curation: 002036
- to stream Istex, to step Checkpoint: 003F92
- to stream PubMed, to step Corpus: 004C65
- to stream PubMed, to step Curation: 004C65
- to stream PubMed, to step Checkpoint: 004B97
- to stream Ncbi, to step Merge: 004870
- to stream Ncbi, to step Curation: 004870
- to stream Ncbi, to step Checkpoint: 004870
- to stream Main, to step Merge: 008F64
- to stream PascalFrancis, to step Corpus: 003756
- to stream PascalFrancis, to step Curation: 003068
- to stream PascalFrancis, to step Checkpoint: 003676
- to stream Main, to step Merge: 009096
- to stream Main, to step Curation: 005D25
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine</title><author><name sortKey="Blunt, S B" sort="Blunt, S B" uniqKey="Blunt S" first="S. B." last="Blunt">S. B. Blunt</name></author><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CA1891C622995BEC8D3F60531905DEAC96B1AD91</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1002/mds.870080202</idno><idno type="url">https://api.istex.fr/document/CA1891C622995BEC8D3F60531905DEAC96B1AD91/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002036</idno><idno type="wicri:Area/Istex/Curation">002036</idno><idno type="wicri:Area/Istex/Checkpoint">003F92</idno><idno type="wicri:doubleKey">0885-3185:1993:Blunt S:suppressive:effect:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8097279</idno><idno type="wicri:Area/PubMed/Corpus">004C65</idno><idno type="wicri:Area/PubMed/Curation">004C65</idno><idno type="wicri:Area/PubMed/Checkpoint">004B97</idno><idno type="wicri:Area/Ncbi/Merge">004870</idno><idno type="wicri:Area/Ncbi/Curation">004870</idno><idno type="wicri:Area/Ncbi/Checkpoint">004870</idno><idno type="wicri:doubleKey">0885-3185:1993:Blunt S:suppressive:effect:of</idno><idno type="wicri:Area/Main/Merge">008F64</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:93-0457152</idno><idno type="wicri:Area/PascalFrancis/Corpus">003756</idno><idno type="wicri:Area/PascalFrancis/Curation">003068</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003676</idno><idno type="wicri:doubleKey">0885-3185:1993:Blunt S:suppressive:effect:of</idno><idno type="wicri:Area/Main/Merge">009096</idno><idno type="wicri:Area/Main/Curation">005D25</idno><idno type="wicri:Area/Main/Exploration">005D25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine</title><author><name sortKey="Blunt, S B" sort="Blunt, S B" uniqKey="Blunt S" first="S. B." last="Blunt">S. B. Blunt</name><affiliation><wicri:noCountry code="subField">King's College</wicri:noCountry></affiliation><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, National Hospital, London</wicri:cityArea></affiliation></author><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name><affiliation><wicri:noCountry code="subField">King's College</wicri:noCountry></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, National Hospital, London</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993">1993</date><biblScope unit="vol">8</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="133">133</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CA1891C622995BEC8D3F60531905DEAC96B1AD91</idno><idno type="DOI">10.1002/mds.870080202</idno><idno type="ArticleID">MDS870080202</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Animals</term><term>Antiparkinson agent</term><term>Carbidopa (pharmacology)</term><term>Cell Count (drug effects)</term><term>Cell Survival (drug effects)</term><term>Dominance, Cerebral (drug effects)</term><term>Dominance, Cerebral (physiology)</term><term>Dopa</term><term>Dopamine (physiology)</term><term>Experimental disease</term><term>Female</term><term>L‐dopa</term><term>Neural Pathways (cytology)</term><term>Neural Pathways (drug effects)</term><term>Neurons (cytology)</term><term>Neurons (drug effects)</term><term>Neurotoxicity</term><term>Oxidopamine (toxicity)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Rat</term><term>Rats</term><term>Rats, Wistar</term><term>Receptors, Dopamine (drug effects)</term><term>Substantia Nigra (cytology)</term><term>Substantia Nigra (drug effects)</term><term>Tegmentum Mesencephali (cytology)</term><term>Tegmentum Mesencephali (drug effects)</term><term>Toxicity</term><term>Tyrosine 3-Monooxygenase (metabolism)</term><term>Ventral tegmental area (VTA)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Carbidopa</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Neural Pathways</term><term>Neurons</term><term>Substantia Nigra</term><term>Tegmentum Mesencephali</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Count</term><term>Cell Survival</term><term>Dominance, Cerebral</term><term>Neural Pathways</term><term>Neurons</term><term>Substantia Nigra</term><term>Tegmentum Mesencephali</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Dominance, Cerebral</term><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Oxidopamine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Rats</term><term>Rats, Wistar</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Antiparkinsonien</term><term>Dopa</term><term>Parkinson maladie</term><term>Pathologie expérimentale</term><term>Rat</term><term>Toxicité</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ever since the introduction of levo‐3, 4‐dihydroxyphenylalanine (L‐dopa) for the treatment of Parkinson's disease, there has been concern that it might accelerate the degeneration of dopamine neurones. Using rats with a unilateral 6‐hydroxydopamine (6‐OHDA) lesion of the medial forebrain bundle (MFB), we have studied the effect of chronic L‐dopa treatment on the survival of dopamine cells which remain in the ventral tegmental area (VTA) ipsilateral to a 6‐OHDA lesion. Following lesion surgery, rats were treated with L‐dopa and carbidopa administered in the drinking water for 27 weeks. At the end of the treatment period, the number of dopamine cells remaining in each of the lesioned and intact substantia nigra (SN) and VTA were assessed, using tyrosine hydroxylase immunohistochemistry. Chronic L‐dopa treatment resulted in an apparent reduction in the number of dopamine neurones remaining in the VTA ipsilateral to the lesion, whereas it had no effect on the number of dopamine cells remaining in the intact SN and VTA. This finding suggests a possible suppressive effect in vivo of L‐dopa on dopamine cells in the midbrain of adult animals that have been previously exposed to 6‐OHDA.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li></region></list><tree><noCountry><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Blunt, S B" sort="Blunt, S B" uniqKey="Blunt S" first="S. B." last="Blunt">S. B. Blunt</name></region><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CA1891C622995BEC8D3F60531905DEAC96B1AD91
|texte= Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine
}}
| This area was generated with Dilib version V0.6.23. |  |